KINS Singapore was established in December 2021, and it sells inner care products such as supplement and skin care products in Singapore and Taiwan developed based on its own research on the gut microbiome and skin microbiome. KINS Singapore is preparing to open KINS’s first in-house clinic in Singapore (scheduled to open in mid-2023) to conduct full-scale research on the relationship between the microbiome and chronic skin diseases and symptoms. KINS Singapore also plans to identify proprietary bacteria strains or pro-/post-biotics that may be commercialized as inner care and skin care products or potentially as a new drug seed.

KINS, which is a Japanese HQ of KINS Singapore, is a healthcare company specializing in microbiome and was established from Dr. Shimokawa’s experience as the chairman of a hospital group in Tokyo, where he treated more than 2,500 patients with chronic diseases by utilizing the indigenous bacteria that exist in the human body and guiding them to improve their lifestyle habits. KINS provides consumer healthcare products and medical services through our clinics and veterinary hospitals based on our proprietary research on the microbiome conducted in our own laboratory in Japan.

VISIT WEBSITE
For further enquiry, please contact Taku Edatsune (CFO)